Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook

Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company’s HIV franchise is not only holding firm but…